AUTL - Autolus shares rise on UK launch capacity expansion plans

Autolus Therapeutics (AUTL) shares jump 7% during premarket trading after the company announces plans to establish global commercial launch capacity in the UK, enabling the company to leverage the expertise and skill base of its employees in the region.The company argued that the revised strategy for the commercial supply of AUTO1, a CD19 CAR T cell investigational therapy, aims to deliver a less capital-intensive commercial manufacturing infrastructure at a lower cost base.Autolus said that the updated plan will be enabled by a combination of the existing clinical trial manufacturing site at The Cell and Gene Therapy Catapult ((CGTC)) facility and a new Autolus facility.In conjunction with the new strategy, Autolus’ lease for the manufacturing and office facility at 9950 Medical Center Drive in Rockville has been mutually terminated, triggering a cash payment to Autolus and ending all of the company’s payment obligations under the lease, it said.

For further details see:

Autolus shares rise on UK launch capacity expansion plans